Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clozapine Reaction Shows Comparative Effectiveness In Transition

Executive Summary

A recent study in The Lancet generated significant attention after showing much lower death rates for schizophrenia sufferers taking the cheap generic antipsychotic clozapine compared with branded drugs

You may also be interested in...

Pfizer's Record-Breaking $2.3 Bil. Settlement with DoJ Imposes New Restrictions on Corporate Behavior

A new corporate integrity agreement requires review of sales rep compensation structure, "needs assessment" of publications.

Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs

Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization

Clozapine Schizophrenia Study May Have No Practical Effect In U.S.

Shaking off stigma of life-threatening blood cell disorder will be almost impossible, says analyst.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts